A longitudinal model for non-monotonic clinical assessment scale data

Journal of Pharmacokinetics and Pharmacodynamics

Volumn 32, Issue 5-6, 2005, Pages 795-815

  Jonsson, Fredrik ^a   Marshall, Scott ^b   Krams, Michael ^b   Jonsson, E Niclas ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

Clinical assessment scales; Dropout; Markovian; Non monotonic; NONMEM; Ordinal data; Stroke

Indexed keywords

RECOMBINANT PROTEIN; UK 279276; UNCLASSIFIED DRUG;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONSCIOUSNESS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONVALESCENCE; DISEASE SEVERITY; DISEASE SIMULATION; DRUG EFFECT; EYE MOVEMENT; FEMALE; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MOTOR PERFORMANCE; NONLINEAR SYSTEM; ORIENTING REFLEX; PHASE 2 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; PROBABILITY; RATING SCALE; SCORING SYSTEM; SPEECH ARTICULATION; STROKE;

ALGORITHMS; AREA UNDER CURVE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIALS, PHASE II; DISEASE PROGRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; GLYCOPROTEINS; HUMANS; LONGITUDINAL STUDIES; MARKOV CHAINS; MODELS, BIOLOGICAL; PATIENT DROPOUTS; SCANDINAVIA; SEVERITY OF ILLNESS INDEX; SOFTWARE; TIME FACTORS; TREATMENT OUTCOME;

EID: 28844466978     PISSN: 1567567X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10928-005-0098-z     Document Type: Article

References (15)

1. L.B. Sheiner J. Wakefield 1999 Population modeling in drug development Stat. Methods. Med. Res. 8 183 93
2. E.N. Jonsson L.B. Sheiner 2002 More efficient clinical trials through use of scientific model-based statistical tests Clin. Pharm. Ther 72 603 614
3. P.L.S. Chan N.H.G. Holford 2001 Drug treatment effects on disease progression Annu. Rev. Pharmacol. Toxicol. 41 625 659
4. FDA. Guidance for Industry: E9 Statistical Principles for Clinical Trials (1998)
5. J.W. Mandema D.R. Stanski 1996 Population pharmacodynamic model for ketorolac analgesia Clin. Pharm. Ther. 60 619 635
6. L.B. Sheiner 1994 A new approach to the analysis of analgesic drug trials, illustrated with bromfenac data Clin. Pharm. Ther. 56 309 322
7. D.J. Lunn J. Wakefield A. Racine-Poon 2001 Cumulative logit models for ordinal data: a case study involving allergic rhinitis severity scores Statist. Med. 20 2261 2285
8. M.K. Olsen J.L. Schafer 2001 A two-part random-effects model for semicontinuous longitudinal data J. Am. Statist. Ass. 96 730 745
9. E.H. Lo T. Dalkara M.A. Moskowitz 2003 Mechanisms, challenges and opportunities in stroke Nat. Rev. Neurosci. 4 399 415
10. K.R. Lees H.-C. Diener K. Asplund M. Krams 2003 UK-279,276, a neutrophil inhibitory glycoprotein, in acute stroke - Tolerability and Pharmacokinetics Stroke. 34 1704 1709
11. Scandinavian Stroke Study Group. 1985 Multicenter trial of hemodilution in ischemic stroke - background and study protocol Stroke. 16 885 890
12. E.N. Jonsson F. [tmp] McIntyre I. James M. Krams S. Marshall 2005 Pharmacokinetic and pharmacodynamic bridging between healthy volunteers and stroke patients for UK-276,279 using a mechanistically based model for target mediated disposition Pharm. Res. 22 1236 1246
13. C. Hu M.E. Sale 2003 A joint model for nonlinear longitudinal data with informative dropout J. Pharmacokin. Pharmacodyn. 30 83 103
14. L. Lindbom J. Ribbing E.N. Jonsson 2004 Perl-speaks-NONMEM (PsN) - A Perl module for NONMEM related programming Comp. Meth. Prog. Biomed 75 85 94
15. M. Krams K.R. Lees W. Hacke A.P. Grieve J.M. Orgogozo G.AA.S. Ford 2003 Investigators. Acute stroke therapy by inhibition of neutrophils (ASTIN): an adaptive dose-response study of UK-279,276 in acute ischemic stroke Stroke. 34 2543 2548